Capital DailyCapital Daily
Markets · Investing · Business
Capital DailyCapital Daily
Finance

AbbVie Has Raised Its Dividend for 53 Straight Years and Still Looks Attractively Valued. Is This Dividend King the Smartest Buy in Healthcare Right Now?

AbbVie still looks like a compelling buy at its all-time high.

AbbVie Has Raised Its Dividend for 53 Straight Years and Still Looks Attractively Valued. Is This Dividend King the Smartest Buy in Healthcare Right Now?

Published July 29, 2026 · Category: Finance

Overview

AbbVie (NYSE: ABBV), one of the world's largest pharmaceutical companies, is usually considered a blue chip dividend stock rather than a higher-growth one. Yet over the past five years, its stock has rallied 125% and delivered a total return of 170% with reinvested dividends.

AbbVie has raised its dividend for 53 consecutive years (including its history as part of Abbott Laboratories (NYSE: ABT) up to 2013), putting it in the elite club of Dividend Kings that have boosted their payouts each year for at least half a century. It also still looks like a bargain at 18 times forward earnings. So is AbbVie one of the best healthcare stocks to buy right now?

Image source: Getty Images.

Details

Continue reading

Source

Originally published at www.fool.com.

Related Articles

CD
Capital Daily Newsroom

Capital Daily covers markets, crypto and commodities for Asia & the Middle East — tier-1 desk research, AI-driven analysis, institutional-grade data. Tip our newsroom: [email protected]

Email the newsroom →
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.